A Phase 2 interventional study of Omaveloxolone capsules, 2.5 mg and omaveloxolone capsules, 5 mg in MItochondrial Myopathies, sponsored by Biogen. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-05.
Sponsored by Biogen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Mitochondrial Myopathies with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Mitochondrial Myopathies · United States.
Among the 19 studies in Mitochondrial Myopathies with a site in United States, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2015, is one of 5 in phase 2, and was the 4th registered.
46 studies on the registry are indexed under Mitochondrial Myopathies; 14 are open to participants now.
Browse Mitochondrial Myopathies studies →6 of the 19 studies in Mitochondrial Myopathies with a site in United States are open now. Recruiting first, the newest first:
The POLG Foundation · Sites in United States, Australia, Denmark and 6 more countries
Children's Hospital of Philadelphia · Sites in United States
Ages 18–65 · Healthy volunteers
Children's Hospital of Philadelphia · Sites in United States
Ages 10–60 · Healthy volunteers
Children's Hospital of Philadelphia · Sites in United States
Ages 18–65 · Healthy volunteers
Children's Hospital of Philadelphia · Sites in United States
Ages 0–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Mitochondrial Myopathies studies recruiting now, 8 (62%) set no upper age limit and 4 (31%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 1
First in 1978; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is above the median of 24 across 31 interventional studies indexed under Mitochondrial Myopathies.
Median enrollment 50 across the 12 interventional studies, 215 across the 7 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 19 have an industry lead sponsor. The 10 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Biogen has 1 study filed under Mitochondrial Myopathies — fewer than ten, so there is no comparison to draw.
5 of the studies in Mitochondrial Myopathies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05590468Ralitza GavrilovaA Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy | 2026-11 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
| NCT04086329Children's Hospital of PhiladelphiaValidation of Oxygen Nanosensor in Mitochondrial Myopathy | 2027-08-01 |
| NCT06819683Children's Hospital of PhiladelphiaValidation of Nanosensor Oxygen Measurement | 2027-09 |
| NCT05569122Children's Hospital of PhiladelphiaApplying pGz in Mitochondrial Disease | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 19 studies in Mitochondrial Myopathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Mitochondrial myopathies are a multisystemic group of disorders that are characterized by a wide range of biochemical and genetic mitochondrial defects and variable modes of inheritance. Currently there are no effective treatments for this disease. Despite the heterogeneous myopathy phenotypes, a unifying feature of mitochondrial myopathies is that the pathogenic mtDNA mutations and/or nuclear mutations of the electron transport chain invariably lead to dysfunctional mitochondrial respiration. This reduction in mitochondrial respiration leads to a reduced ability to produce cellular adenosine triphosphate (ATP), often resulting in muscle weakness, exercise intolerance, and fatigue in patients with mitochondrial myopathies.
RTA 408 is a potent activator of Nrf2 and inhibitor of NF κB (nuclear factor kappa-light-chain-enhancer of activated B cells), and thus induces an antioxidant and anti-inflammatory phenotype. Several lines of evidence suggest that Nrf2 activation can increase mitochondrial respiration and biogenesis. Collectively, available data suggest that the ability of RTA 408 to activate Nrf2 and induce its target genes could potentially improve muscle function, oxidative phosphorylation, antioxidant capacity, and mitochondrial biogenesis in patients with mitochondrial myopathies.
This study will be a randomized, placebo-controlled, double-blind, dose-escalation study to evaluate the safety of omaveloxolone (RTA 408) at various doses in patients with mitochondrial myopathies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have mitochondrial myopathy as evidenced by the following 2 criteria (must meet both):
Exclusion Criteria:
Have taken any of the following drugs within 7 days prior to Study Day 1 or plan to take any of these drugs during the time of study participation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally once daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
Drug: Omaveloxolone capsules, 2.5 mg · Drug: omaveloxolone capsules, 5 mg
omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 12 weeks
Drug: omaveloxolone capsules, 10 mg
Placebo capsules taken orally once daily for 12 weeks
Drug: Placebo capsules
omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks.
Drug: omaveloxolone capsules, 20 mg
omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks.
Drug: omaveloxolone capsules, 40 mg
omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks.
Drug: omaveloxolone capsules, 80 mg
omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks.
Drug: omaveloxolone capsules, 160 mg
Also known as: RTA 408 Capsules 2.5 mg
Also known as: RTA 408 capsules, 5 mg
Also known as: RTA 408, 10 mg
Also known as: RTA 408 capsules, 20 mg
Also known as: RTA 408 capsules, 40 mg
Also known as: RTA 408 capsules, 80 mg
Also known as: RTA 408 capsules, 160 mg
Change of Peak Workload (in Watts/kg) During Exercise Testing
Cycle ergometry using a stationary recumbent bike was used to conduct maximal exercise testing. Peak work is defined as the workload at which patients reach maximal volition (defined as an inability to continue to exercise due to exhaustion). Change of peak workload during exercise testing was measured at baseline, Week 4, and Week 12. Change from baseline at Week 12 reported.
Time frame: 12 weeks
Change in 6-minute Walk Test (6MWT) Distance
Patients were instructed to walk as far as they could along a marked path for 6 minutes. Distance walked was measured. If patients used a cane or walking assist device at Screening, the same walking assist device was to be used for all 6MWT assessments.
Time frame: 6MWT was assessed at Week 4, Week 8, and Week 12 and compared to baseline
First patient enrolled 5-May-2015, last patient completed 30-Nov-2017
| Milestone | Placebo | Omaveloxolone Capsules 2.5 and 5 mg | Omaveloxolone Capsules 10 mg | Omaveloxolone Capsules 20 mg | Omaveloxolone Capsules 40 mg | Omaveloxolone Capsules 80 mg | Omaveloxolone Capsules 160 mg |
|---|---|---|---|---|---|---|---|
| Started | 13 | 6 | 6 | 6 | 6 | 6 | 10 |
| Completed | 13 | 6 | 5 | 6 | 6 | 6 | 8 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Cycle ergometry using a stationary recumbent bike was used to conduct maximal exercise testing. Peak work is defined as the workload at which patients reach maximal volition (defined as an inability to continue to exercise due to exhaustion). Change of peak workload during exercise testing was measured at baseline, Week 4, and Week 12. Change from baseline at Week 12 reported.
| Watts/kg | Placebo | Omaveloxolone Capsules 2.5 and 5 mg | Omaveloxolone Capsules 10 mg | Omaveloxolone Capsules 20 mg | Omaveloxolone Capsules 40 mg | Omaveloxolone Capsules 80 mg | Omaveloxolone Capsules 160 mg |
|---|---|---|---|---|---|---|---|
| Change of Peak Workload (in Watts/kg) During Exercise Testing | 0.0090 ± 0.0388 | 0.020 ± 0.0544 | -0.0300 ± 0.0544 | 0.1050 ± 0.0596 | -0.0520 ± 0.0544 | -0.0660 ± 0.0544 | 0.0020 ± 0.0465 |
Patients were instructed to walk as far as they could along a marked path for 6 minutes. Distance walked was measured. If patients used a cane or walking assist device at Screening, the same walking assist device was to be used for all 6MWT assessments.
| Meters | Placebo | Omaveloxolone Capsules 2.5 and 5 mg | Omaveloxolone Capsules 10 mg | Omaveloxolone Capsules 20 mg | Omaveloxolone Capsules 40 mg | Omaveloxolone Capsules 80 mg | Omaveloxolone Capsules 160 mg |
|---|---|---|---|---|---|---|---|
| Week 4 | 40.462 ± 10.0539 | 19.333 ± 14.9658 | 18.2500 ± 14.9658 | -9.2000 ± 16.3942 | -11.6670 ± 14.9658 | 9.9170 ± 14.9658 | 10.8330 ± 12.2195 |
| Week 8 | 24.923 ± 9.9381 | 12.865 ± 15.7374 | 33.9170 ± 15.1418 | 13.8000 ± 16.5870 | 11.0000 ± 15.1418 | 17.5830 ± 15.1418 | 28.9440 ± 12.3633 |
| Week 12 | 29.846 ± 12.9276 | 17.167 ± 19.6519 | 17.7500 ± 19.6519 | 28.2000 ± 21.5275 | -7.833 ± 19.6519 | 6.2500 ± 19.6519 | 8.5710 ± 16.4721 |
Collected over 16 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/13 (0%) | 1/13 (7.7%) | 11/13 (84.6%) |
| Omaveloxolone Capsules 2.5 and 5 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Omaveloxolone Capsules 10 mg | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Omaveloxolone Capsules 20 mg | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Omaveloxolone Capsules 40 mg | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Omaveloxolone Capsules 80 mg | 0/6 (0%) | 1/6 (16.7%) | 4/6 (66.7%) |
| Omaveloxolone Capsules 160 mg | 0/10 (0%) | 1/10 (10%) | 10/10 (100%) |
| Event | Placebo | Omaveloxolone Capsules 2.5 and 5 mg | Omaveloxolone Capsules 10 mg | Omaveloxolone Capsules 20 mg | Omaveloxolone Capsules 40 mg | Omaveloxolone Capsules 80 mg | Omaveloxolone Capsules 160 mg |
|---|---|---|---|---|---|---|---|
| Wide complex tachycardiaCardiac disorders | 0/13 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/10 |
| Optic neuritisNervous system disorders | 0/13 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/10 |
| Right sided hemiparesisNervous system disorders | 0/13 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/10 |
| Exacerbated fatigueGeneral disorders | 0/13 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/10 |
| Atrioventricular dissociationCardiac disorders | 0/13 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/10 |
| Ventricular tachycardiaCardiac disorders | 0/13 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/10 |
| Tonic epileptic seizureNervous system disorders | 1/13 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 |
| Event | Placebo | Omaveloxolone Capsules 2.5 and 5 mg | Omaveloxolone Capsules 10 mg | Omaveloxolone Capsules 20 mg | Omaveloxolone Capsules 40 mg | Omaveloxolone Capsules 80 mg | Omaveloxolone Capsules 160 mg |
|---|---|---|---|---|---|---|---|
| MyalgiaMusculoskeletal and connective tissue disorders | 0/13 | 0/6 | 4/6 | 0/6 | 0/6 | 0/6 | 0/10 |
| FatigueGeneral disorders | 4/13 | 0/6 | 3/6 | 0/6 | 0/6 | 1/6 | 1/10 |
| DiarrhoeaGastrointestinal disorders | 3/13 | 1/6 | 1/6 | 2/6 | 1/6 | 1/6 | 2/10 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/13 | 2/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/10 |
| HeadacheNervous system disorders | 0/13 | 1/6 | 1/6 | 2/6 | 0/6 | 0/6 | 1/10 |
| DizzinessNervous system disorders | 1/13 | 0/6 | 2/6 | 0/6 | 1/6 | 0/6 | 0/10 |
| Upper respiratory tract infectionInfections and infestations | 2/13 | 1/6 | 0/6 | 1/6 | 1/6 | 0/6 | 3/10 |
| Back painMusculoskeletal and connective tissue disorders | 3/13 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/10 |
| NauseaGastrointestinal disorders | 1/13 | 0/6 | 1/6 | 1/6 | 0/6 | 0/6 | 2/10 |
| VomitingGastrointestinal disorders | 1/13 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 2/10 |
All 53 patients were included in the baseline population
| Age, Continuous(Years) | Placebo | Omaveloxolone Capsules 2.5 and 5 mg | Omaveloxolone Capsules 10 mg | Omaveloxolone Capsules 20 mg | Omaveloxolone Capsules 40 mg | Omaveloxolone Capsules 80 mg | Omaveloxolone Capsules 160 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 41.1 ± 11.86 | 52.3 ± 9.61 | 49.8 ± 14.05 | 45.5 ± 14.08 | 45.2 ± 4.71 | 30.7 ± 10.25 | 39.8 ± 15.27 | 42.9 ± 13.01 |
| Sex: Female, Male(Participants) | Placebo | Omaveloxolone Capsules 2.5 and 5 mg | Omaveloxolone Capsules 10 mg | Omaveloxolone Capsules 20 mg | Omaveloxolone Capsules 40 mg | Omaveloxolone Capsules 80 mg | Omaveloxolone Capsules 160 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 9 | 1 | 3 | 4 | 5 | 4 | 6 | 32 |
| Male | 4 | 5 | 3 | 2 | 1 | 2 | 4 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Omaveloxolone Capsules 2.5 and 5 mg | Omaveloxolone Capsules 10 mg | Omaveloxolone Capsules 20 mg | Omaveloxolone Capsules 40 mg | Omaveloxolone Capsules 80 mg | Omaveloxolone Capsules 160 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 1 | 0 | 0 | 0 | 3 | 6 |
| Not Hispanic or Latino | 11 | 6 | 5 | 6 | 6 | 6 | 7 | 47 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
Ran from May 2015 to primary completion in Nov 2017, 29 months.
Results were first posted in Sep 2020, 2 years 10 months after primary completion. A results delay was requested in Jul 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.